DM-101PX

BIOLOGICAL2 trials

Sponsors

Desentum Oy

Conditions

Birch Pollen Allergy

Phase 1

Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants

CompletedNCT06037148

Desentum OyBirch Pollen Allergy

Start: 2023-09-07End: 2024-03-06Updated: 2024-03-25

Phase 2

Study of DM-101PX in Adults With Birch Pollen Allergy

CompletedNCT07254871

Desentum OyBirch Pollen Allergy

Start: 2025-09-26End: 2026-08-10Updated: 2026-08-31

Related Papers

Subcutaneous Allergen Immunotherapy With Thermosensitive Hydrogel and Recombinant Birch Pollen Allergen Variant, a Randomised Controlled Trial

Clinical & Experimental Allergy2026-08-31